| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T142 |
0-146 |
Sentence |
denotes |
There is no available vaccine against COVID-19, while previous vaccines or strategies used to develop a vaccine against SARS-CoV can be effective. |
| T143 |
147-349 |
Sentence |
denotes |
Recombinant protein from the Urbani (AY278741) strain of SARS-CoV was administered to mice and hamsters, resulted in the production of neutralizing antibodies and protection against SARS-CoV [56], [57]. |
| T144 |
350-542 |
Sentence |
denotes |
The DNA fragment, inactivated whole virus or live-vectored strain of SARS-CoV (AY278741), significantly reduced the viral infection in various animal models [58], [59], [60], [61], [62], [63]. |
| T145 |
543-701 |
Sentence |
denotes |
Different other strains of SARS-CoV were also used to produce inactivated or live-vectored vaccines which efficiently reduced the viral load in animal models. |
| T146 |
702-946 |
Sentence |
denotes |
These strains include, Tor2 (AY274119) [64], [65], Utah (AY714217) [66], FRA (AY310120) [59], HKU-39849 (AY278491) [57], [67], BJ01 (AY278488) [68], [69], NS1 (AY508724) [70], ZJ01 (AY297028) [70], GD01 (AY278489) [69] and GZ50 (AY304495) [71]. |
| T147 |
947-1014 |
Sentence |
denotes |
However, there are few vaccines in the pipeline against SARS-CoV-2. |
| T148 |
1015-1158 |
Sentence |
denotes |
The mRNA based vaccine prepared by the US National Institute of Allergy and Infectious Diseases against SARS-CoV-2 is under phase 1 trial [72]. |
| T149 |
1159-1232 |
Sentence |
denotes |
INO-4800-DNA based vaccine will be soon available for human testing [73]. |
| T150 |
1233-1359 |
Sentence |
denotes |
Chinese Centre for Disease Control and Prevention (CDC) working on the development of an inactivated virus vaccine [74], [75]. |
| T151 |
1360-1453 |
Sentence |
denotes |
Soon mRNA based vaccine’s sample (prepared by Stermirna Therapeutics) will be available [76]. |
| T152 |
1454-1543 |
Sentence |
denotes |
GeoVax-BravoVax is working to develop a Modified Vaccina Ankara (MVA) based vaccine [77]. |
| T153 |
1544-1658 |
Sentence |
denotes |
While Clover Biopharmaceuticals is developing a recombinant 2019-nCoV S protein subunit-trimer based vaccine [78]. |
